Cocrystals are neutral crystalline solids containing API and coformer. They can tune aqueous solubility, dissolution, hygroscopicity, highly disordered desolvated-solvate behavior, lipophilicity, bioavailability, stability, melting point, API purity, developability, and intellectual property position.
Cocrystals can create crystalline forms of APIs previously known only as amorphous forms, improve melting points, improve chemical purity, reduce light-related degradation, reduce hydrate risk in formulation, and improve solubility or bioavailability.
A cocrystal screen is usually considered when a suitable salt cannot be found, the molecule is non-ionizable, or a crystalline property-improvement and IP strategy is needed.
The development value of a cocrystal depends on a measurable property gain and a credible path to control. If the cocrystal improves solubility but converts to the parent API during dissolution or storage, the program needs residual-solid analysis and formulation mitigation before the form is treated as a lead.
Triclinic uses an expanded coformer list and a phase-diagram-guided approach rather than relying only on generic combinatorial screening. Establishing phase relationships can support a more intelligent approach to solid-form screening and can help predict undiscovered solid forms or instability.
Cocrystal hits are characterized by melting behavior, stoichiometric domains, XRPD and/or Raman fingerprints, and downstream performance. Reaction conditions include stoichiometric wet milling and solvent-drop grinding, non-stoichiometric slurry conversion, thermal methods, mechanical processing, sonication, Kofler/binary melt methods, and individual vial screening where appropriate.
Phase relationships also reduce false confidence. A new thermal event or pattern shift can be a useful clue, but it should be tied to stoichiometry, stability domain, and reproducible preparation before it is used to support form selection or IP strategy.
Cocrystal formulation is often a supersaturation problem. The cocrystal can set the spring by generating a higher API concentration, but formulation must open the parachute by delaying crystallization long enough for absorption.
Higher cocrystal loading does not automatically improve exposure. Once supersaturation is too high, API crystallization can accelerate and reduce the benefit. Therefore cocrystal selection should include dissolution, crystallization-inhibition, and formulation stress experiments.
A cocrystal program should not stop at a new XRPD pattern. The decision is whether the new multicomponent crystal improves a property that matters and remains controllable during crystallization, formulation, storage, dissolution, release testing, and lifecycle changes.
Triclinic uses coformer selection, reaction-condition diversity, phase-diagram logic, and orthogonal characterization to separate true cocrystals from salts, eutectics, physical mixtures, solvates, hydrates, and metastable artifacts.
Cocrystals are strategic when the API is non-ionizable, salt formation fails, or the program needs to tune solubility, hygroscopicity, stability, purification, chiral resolution, mechanical properties, bioavailability, or IP position.
A cocrystal screen should begin with API evaluation and coformer selection, then move into experimental design. Useful inputs can include hydrogen-bond donor/acceptor complementarity, symmetry, salt-forming potential, molecular electrostatic potential, coformer safety, size and flexibility, solubility, and chemical stability.
| Decision signal | What to test | Actionable output |
|---|---|---|
| Non-ionizable API | Provides a solid-form option when proton-transfer salt formation is unavailable. | Select coformers rationally and confirm the resulting solid state. |
| Salt failure | Can improve properties without relying on a problematic counterion. | Compare cocrystal behavior against salt, free form, and formulation alternatives. |
| Hygroscopicity or stability issue | A coformer may reduce water uptake or stabilize a troublesome form. | Stress candidate forms under humidity, solvent, and formulation-relevant conditions. |
| Purification or chiral selectivity | Crystal packing can reject impurities or discriminate between components. | Document solid-form identity and property relevance. |
A Purdue Pharma cocrystal example illustrates how a cocrystal can show improved dissolution and in vivo exposure relative to the parent API form when formulation and physical stability are aligned.
Determine whether an API can exist in multiple crystalline forms and whether form differences change solubility, dissolution, stability, manufacturing, drug-product performance, or IP.
View serviceScreen ionizable APIs for counterions that improve crystallinity, solubility, dissolution, stability, manufacturability, or developability while controlling disproportionation risk.
View serviceCharacterize non-crystalline materials, local order, recrystallization risk, spray drying feasibility, polymer selection, drug loading, and solid-dispersion stability.
View serviceBuild reproducible crystallization processes that control the chosen solid form, particle attributes, purity, and scale-up behavior.
View serviceResolve form conversion, failed crystallizations, process sensitivity, stability drift, unexplained PK/dissolution changes, and batch-to-batch material differences.
View serviceWhen a suitable salt cannot be found, when the molecule is non-ionizable, when the neutral form lacks required properties, or when IP and lifecycle options are important.
They help map stoichiometric domains and phase relationships so cocrystal hits can be interpreted rather than treated as isolated screening outcomes.
A developable cocrystal must improve a relevant property and remain controllable during formulation, storage, dissolution, release testing, and lifecycle changes.
A cocrystal hit is not the same thing as a developable cocrystal. Some screens produce new patterns that are salts, solvates, hydrates, eutectics, physical mixtures, or metastable forms that disappear when conditions change. The hard part is not producing a hit; it is proving identity, stoichiometry, phase stability, salt-versus-cocrystal classification, and property improvement under the conditions the drug product will actually see. A useful cocrystal program also asks whether the cocrystal creates a formulation problem: supersaturation may improve exposure only if crystallization is delayed long enough to matter.
Classification may require pKa context, vibrational spectroscopy, thermal analysis, XRPD, and—when needed—single-crystal X-ray diffraction, MicroED, solid-state NMR, or other structure-sensitive evidence. A new powder pattern alone does not prove cocrystal identity.
Send the material history, current data package, process conditions, development objective, and timeline. Triclinic will route the request to the right solid-form scientist.
